Global Oncology Academy

The Role of GPRC5D in the Multiple Myeloma Treatment Paradigm

ReachMD Healthcare Image

How do clinicians manage patients with relapsed or refractory multiple myeloma? And what are the new generation of therapies focusing on?

  • Overview

    GPRC5D has become a key potential target for many newer multiple myeloma therapies. So how could this address gaps in the current treatment landscape? Dive in with Dr. Charles Turck as he discusses this with Dr. Joshua Richter, Associate Professor of Medicine at the Tisch Cancer Institute in the Division of Hematology and Oncology and the Director of Multiple Myeloma at the Blavatnik Family Chelsea Medical Center at Mount Sinai in New York.

Facebook Comments



We’re glad to see you’re enjoying Global Oncology Academy…
but how about a more personalized experience?

Register for free